Protection of IFN-gamma signaling-deficient NOD mice from diabetes by cyclophosphamide
Related Experiment Video
Updated: Jul 3, 2026
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Yoshiko Mori1, Takako Kato, Tetsuro Kodaka
1Laboratory for Autoimmune Regulation, RIKEN Center for Allergy and Immunology, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.
Abstract:
Non-obese diabetic (NOD) mice that are genetically deficient in either IFN-gamma or beta chain of the IFN-gammaR develop diabetes with similar kinetics to wild-type NOD mice. In the current study, we demonstrated that treatment of IFN-gamma signaling-deficient NOD mice with cyclophosphamide (CY) not only fails to induce acute diabetes but also confers permanent protection from diabetes. Protection was mediated by the preferential generation of regulatory T cells (Treg cells) that are capable of suppressing the diabetogenic process, with no change in the total number and function of Treg cells. Moreover, CY treatment of IFN-gamma signaling-deficient NOD mice reversed the ongoing pathogenic process and eliminated cellular infiltrates of pancreatic islets. While these results have been derived using a genetically modified mouse model of diabetes, they indicate that knowledge of host genetic factors and environmental factors influencing the development of Type I diabetes mellitus may provide a rational approach to develop a means to reverse the development of Type I diabetes in human.
Insights
Cyclophosphamide (CY) treatment permanently protects genetically modified mice lacking IFN-gamma signaling from developing Type 1 diabetes. This protection stems from enhanced regulatory T cells, offering potential insights for reversing human diabetes.
Area of Science:
- Immunology
- Endocrinology
- Genetics
Background:
- Non-obese diabetic (NOD) mice genetically deficient in IFN-gamma signaling develop diabetes similarly to wild-type mice.
- Understanding the role of IFN-gamma signaling in diabetes pathogenesis is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the effect of cyclophosphamide (CY) treatment on diabetes development in IFN-gamma signaling-deficient NOD mice.
- To elucidate the mechanisms underlying CY-induced protection from diabetes in this model.
Main Methods:
- Treatment of IFN-gamma signaling-deficient NOD mice with cyclophosphamide (CY).
- Assessment of diabetes incidence and kinetics.
- Analysis of regulatory T cell (Treg) populations and function.
- Histological examination of pancreatic islets for cellular infiltrates.
Main Results:
- CY treatment failed to induce acute diabetes and conferred permanent protection in IFN-gamma signaling-deficient NOD mice.
- Protection was associated with preferential generation of regulatory T cells (Treg cells) that suppressed the diabetogenic process.
- CY treatment reversed ongoing pathogenic processes and eliminated pancreatic islet cellular infiltrates.
Conclusions:
- IFN-gamma signaling plays a critical role in the pathogenesis of Type 1 diabetes in NOD mice.
- Cyclophosphamide can induce long-term protection from diabetes by modulating regulatory T cell responses.
- These findings suggest that understanding host genetic and environmental factors could lead to strategies for reversing Type 1 diabetes in humans.
